STOCK TITAN

Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

GAITHERSBURG, Md., May 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday, May 9, 2023. Details of the event and replay are as follows:

Conference call details:


Date:

May 9, 2023

Time:

8:30 a.m. U.S. Eastern Daylight Time (EDT)

Dial-in number:

(877) 883-0383 (Domestic) or (412) 902-6506 (International) 

Passcode:

3370620

Webcast:

ir.novavax.com/events

  • Participants will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

Replay details:


Date:

Available starting at 11:30 a.m. EDT, May 9, 2023, until 11:59 p.m. U.S. EDT, May 16, 2023

Dial-in number:            

(877) 344-7529 (Domestic) or (412) 317-0088 (International)

Passcode:

1969560

Webcast:

ir.novavax.com/events, until August 7, 2023

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Ali Chartan
240-720-7804
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2023-financial-results-and-operational-highlights-on-may-9-2023-301812543.html

SOURCE Novavax, Inc.

Novavax Inc

NASDAQ:NVAX

NVAX Rankings

NVAX Latest News

NVAX Stock Data

627.60M
125.20M
4.99%
56.33%
31.37%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG

About NVAX

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.